Money and murder: the dark side of the Asilomar meeting on recombinant DNA
By Matthew Cobb,
Nature
| 02. 17. 2025
On 24 February 1975, some 150 people met at the Asilomar Conference Grounds near Monterey on the Californian coast. They were mostly scientists from the United States, together with representatives of various companies and government agencies, and 16 journalists. Their subject was the new technology of recombinant DNA — molecules created in a laboratory by stitching together genetic material from different organisms. Researchers were excited by the possibilities for discoveries, and the potential of the technique to produce drugs, for example using specially engineered bacteria to make insulin. But they were also terrified that they might inadvertently create diseases that could infect lab workers and the wider community.
By the end of the meeting, its participants had agreed to adopt biosafety protocols that are still in force in the United States, and which have hugely influenced similar regulations worldwide. The meeting has become known simply as Asilomar, a byword for how a scientific community came together to forge consensus on a thorny topic. It is often held up as an example of how science can self-regulate without the involvement of...
Related Articles
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...